An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in the mRNA-3705-P101 Study

  • End date
    Apr 2, 2034
  • participants needed
  • sponsor
    ModernaTX, Inc.
Updated on 26 April 2022


The primary objective of this study is to evaluate the long-term safety of mRNA-3705 administered to participants with methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in Study mRNA-3705-P101 (NCT04899310).


Participants with MMA due to MUT deficiency who were previously enrolled, completed the Treatment Period, and completed the end of treatment (EOT) Visit of the mRNA-3705-P101 study will have the option to enroll into this extension study provided all eligibility criteria have been met. The study will include 2 periods: 1) Treatment Period and 2) Follow-up Period (up to 2 years after the last dose of study drug).

Treatment Period will continue unless one of the following occurs: mRNA-3705 receives marketing approval and reimbursement in the country of origin of the participant, the participant discontinues study drug, the participant is no longer receiving clinical benefit (in the opinion of the Investigator), or Sponsor discontinues the development of mRNA-3705.

Condition Methylmalonic Acidemia
Treatment mRNA-3705
Clinical Study IdentifierNCT05295433
SponsorModernaTX, Inc.
Last Modified on26 April 2022


Yes No Not Sure

Inclusion Criteria

Completed the mRNA-3705-P101 assigned dose regimen treatment time period
Completed the EOT Visit in Study mRNA-3705-P101 within 10 days of first dose of mRNA-3705 in the current study

Exclusion Criteria

Not expected to receive clinical benefit from continued mRNA-3705 administration, in the opinion of the Investigator
Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study
History of liver and/or kidney transplant
NOTE: Other inclusion and exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note